Our study addresses these issues by identifying the oncogenic pseudokinase PEAK1 as a feed-forward activator of CAMK2 and the second-generation CAMK2D/G inhibitor RA306 as a suitable targeted agent to block PEAK1/CAMK2 signalling in TNBC and other cancers where PEAK1 is involved, such as pancreatic cancer. Here, CAMK2B is linked to familial pancreatic carcinoma.